A detailed history of Rhumbline Advisers transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 350 shares of ANVS stock, worth $1,561. This represents 0.0% of its overall portfolio holdings.

Number of Shares
350
Holding current value
$1,561
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.27 - $15.46 $1,844 - $5,411
350 New
350 $2,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $36.4M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.